The Rundown – September 22, 2025

Episode Title: Trump's H-1B Visa Plan Sparks Corporate Chaos, Snap Catches Meme Stock Fever
Host: Zaid Admani
Podcast by: Public.com
Duration: ~10 minutes

Overview

In this episode, Zaid Admani delivers a concise market update, spotlighting major developments: a new Trump-era $100,000 H-1B visa fee and its ripple effects on the tech and finance industries, the ongoing boom in gold, crypto market volatility, Pfizer’s bold move into weight loss drugs, a meme stock frenzy around Snap, fresh controversy for Tylenol, and a surprising insight on why Siri’s flaws haven’t deterred iPhone buyers.

Key Discussion Points and Insights

1. Market Recap & Sentiment

• Strong Equities Rally:

  • S&P 500 up 1.2% last week
  • NASDAQ up 2.2%
  • Optimism fueled by Fed interest rate cuts and hints of more to come
  • “The vibes seem to be good right now on Wall Street as the Fed cuts interest rates…” (00:32)

• Crypto Selloff:

  • Widespread sell-off, $1.5B wiped out
  • Ether, Solana, XRP each down 6–7%
  • Bitcoin held up better, down ~2%, dipped below $113,000
  • Despite lower rates, crypto underperforms expectations
  • “Now, this is a bit surprising because lower interest rates tend to be better for risky assets like crypto. But that doesn't seem to be the case right now.” (01:20)

• Gold Soars:

  • New highs: $3,700/oz, up 10% this month, 40% YTD—beating even Nvidia and Bitcoin
  • “So it’s safe to say that 2025 is shaping up to be the year of gold.” (01:47)

• Upcoming Economic Data:

  • PCE inflation report (Friday) is the Fed’s preferred measure
  • Major earnings: Micron (Tuesday), Costco (Thursday)

2. H-1B Visa Policy Shake-up (Trump Administration)

• Surprise Executive Rule:

  • New $100,000 one-time fee for each new H-1B visa
  • Rule announced Friday, enforced by Sunday (less than 48 hours notice)
  • Immediate chaos:
    • Major companies (Google, Amazon, Microsoft, Goldman Sachs) sent urgent memos to foreign workers
    • Initial confusion—fears fee would impact returning H-1B holders; clarified Saturday to apply only to new applicants

• Industry Impact:

  • Amazon: >10,000 H-1B employees; Google, Meta, Apple, Microsoft also heavily reliant
  • Spans beyond tech: health care, academia, manufacturing
  • “It’s not just tech now.” (04:13)

• Political and Economic Implications:

  • Trump frames move as protecting American workers, curbing “spamming” of visa system
  • Critics: hinders competitiveness and talent inflow, may push jobs overseas
  • US–India tensions:
    • 70% of H-1B visas go to Indians
    • Trump imposed recent 50% tariffs on Indian exports due to India’s Russian oil purchases
    • “So things just got messier and this new rule will likely be challenged in court as well, so expect more uncertainty and chaos ahead.” (05:12)

3. Pfizer’s Big Bet on Weight Loss Drugs

• $7.3B Acquisition of Metcera:

  • Metcera: aspiring to launch once-monthly injectable weight loss drug (potentially more convenient than existing weekly options)
  • Early trials: 8% weight loss in just over a month
  • “Pfizer desperately needs this acquisition to work because they are looking for a new growth engine.” (06:04)

• Desperation for Growth:

  • Pfizer lagging in the weight loss drug arms race after its prior program failed (liver issues)
  • COVID vaccine/pill revenue collapse: $38B peak → $11B last year
  • Major blockbusters going off-patent soon

• Investor Reaction:

  • Pfizer stock up 3%
  • Metcera up over 60% following news

4. Meme Stock Rally: Snap

• Snap Surges on Reddit Hype:
  • Shares up nearly 10%
  • Chatter on WallStreetBets about Snap as an acquisition target
  • Snap’s AR glasses at center—decade+ of R&D, $3B invested
  • “Snap showed off some early prototypes and they are kind of ugly to be honest, but the tech is pretty cool…” (07:09)
  • Possible big tech suitors interested mainly in AR glasses technology
  • Comparison with Meta’s new smart glasses (Deep Dive discussed on previous episode)
  • Host muses about expense: “I’m still debating if I want to buy these glasses and they're $800, so kind of expensive. But as a Meta shareholder, I feel like it’s my duty to review them.” (08:08)

5. Tylenol & Autism: New Controversy

• Kenvue (Tylenol Maker) Shares Slide:
  • Trump administration and Health Secretary RFK Jr. set to claim link between prenatal Tylenol use and autism
  • Kenvue pushing back via NBC and new website section—no proven medical connection after a decade of research
  • Still, investor nerves impacted: “Headlines like this can spook investors, and shares of Kenvue are sliding this morning.” (09:00)

6. Apple, Siri, and What Sells iPhones

• Siri’s Missed Potential:

  • Siri began as third-party app, acquired and integrated after Steve Jobs' personal interest in 2010
  • Little improvement since 2011; founders departed after Jobs' death
  • “While Siri was great in 2011, it seems like Apple hasn’t done any updates in the last 14 years.” (09:27)

• Voice Assistant Not a Sales Driver:

  • Despite Siri’s lagging intelligence, iPhone 17 outselling iPhone 16
  • “Maybe a smart voice assistant isn’t really the deciding factor when it comes to people buying a phone. At least not yet.” (10:05)

Notable Quotes & Memorable Moments

• On sudden visa rule chaos:

  • “The initial rollout was total chaos… There was initial fears that the $100,000 fee would apply to H1B holders reentering the country. By Saturday morning, though the administration clarified that the fee only applied to new applicants.” (03:42)

• On gold’s dominance:

  • “Gold continues to be unstoppable. Prices hit a record high this morning, jumping past $3,700 an ounce. The price of gold is up nearly 10% in the past month and up 40% for the year, which is better performing than Nvidia and Bitcoin.” (01:42)

• On personal investing decisions:

  • “But as a Meta shareholder, I feel like it’s my duty to review them. At least that’s the excuse that I’m going to be telling my wife if I do end up buying these things.” (08:26)

• On Apple’s priorities:

  • “AI software doesn’t seem to be that important right now when it comes to selling phones… maybe a smart voice assistant isn’t really the deciding factor.” (10:05)

Timestamps for Important Segments

• 00:32 – Market optimism; Equities rally
• 01:06 – Crypto selloff, Gold’s record run
• 02:18 – Preview of upcoming PCE inflation data, Earnings week highlights
• 03:01 – Trump administration’s H-1B visa fee bombshell
• 05:12 – Industry and political responses; US–India dynamics
• 05:56 – Pfizer’s Metcera acquisition and the weight loss drug race
• 07:09 – Snap’s meme stock moment, AR glasses as acquisition bait
• 08:08 – Meta smart glasses personal anecdote
• 09:00 – Kenvue/Tylenol autism controversy and market reaction
• 09:27 – Siri’s origin story and stagnation
• 10:05 – iPhone 17 sales, Siri’s irrelevance to consumer purchase decisions

Conclusion

In this brisk episode, Zaid Admani covers a broad sweep of market-shaking news: from the shock and confusion of Trump’s H-1B visa fee and its implications for tech talent, through the exceptional gilded returns in gold and surprises in crypto, to the fierce pharmaceutical pivot at Pfizer, the meme stock rise for Snap amid an AR arms race, and a timely look at both health and tech controversies. Despite Siri’s ongoing frustrations, Apple’s sales remain robust, proving that sometimes shiny hardware still wins over lagging software.

This episode is essential listening for anyone investing, following market dynamics, or interested in how policy twists can rock corporate America in real time.